Publication: Myofibroblast-Derived SFRP1 as Potential Inhibitor of Colorectal Carcinoma Field Effect
Open/View Files
Date
2014
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Valcz, G., Á. V. Patai, A. Kalmár, B. Péterfia, I. Fűri, B. Wichmann, G. Műzes, et al. 2014. “Myofibroblast-Derived SFRP1 as Potential Inhibitor of Colorectal Carcinoma Field Effect.” PLoS ONE 9 (11): e106143. doi:10.1371/journal.pone.0106143. http://dx.doi.org/10.1371/journal.pone.0106143.
Research Data
Abstract
Epigenetic changes of stromal-epithelial interactions are of key importance in the regulation of colorectal carcinoma (CRC) cells and morphologically normal, but genetically and epigenetically altered epithelium in normal adjacent tumor (NAT) areas. Here we demonstrated retained protein expression of well-known Wnt inhibitor, secreted frizzled-related protein 1 (SFRP1) in stromal myofibroblasts and decreasing epithelial expression from NAT tissues towards the tumor. SFRP1 was unmethylated in laser microdissected myofibroblasts and partially hypermethylated in epithelial cells in these areas. In contrast, we found epigenetically silenced myofibroblast-derived SFRP1 in CRC stroma. Our results suggest that the myofibroblast-derived SFRP1 protein might be a paracrine inhibitor of epithelial proliferation in NAT areas and loss of this signal may support tumor proliferation in CRC.
Description
Other Available Sources
Keywords
Biology and life sciences, Biochemistry, DNA, DNA modification, DNA methylation, Genetics, Cancer Genetics, Proto-Oncogenes, Epigenetics, Medicine and Health Sciences, Oncology, Basic Cancer Research, Tumor Physiology, Cancers and Neoplasms, Colorectal Cancer
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service